Author: KKK
BIO, once considered the leader of the "Research and Crypto Fusion" track, has been under pressure since its launch in January this year. Despite having top investors including V and CZ, it could not escape the dual impact of market conditions and liquidity, with its market value shrinking by 95% from its peak, becoming the focus of community dissatisfaction and questioning, and pushing the track that once created market cap miracles like $RIF and $URO into a low point.
However, with the recent launch of BIO Protocol V2, introducing new mechanisms such as Launchpad and Staking points, the total Staking volume broke through 100 million BIO within a week of launch, and the market value quickly doubled to over $200 million, reigniting market attention and imagination for the DeSci track.
Why Did the Luxurious $BIO Fall from Grace?
BIO's listing was originally a highlight of the DeSci track: top exchanges like Binance, OKX, and Kraken all participated, with first-day trading volume exceeding $2 billion, and FDV once reaching $250 million, becoming the most sensational scientific crypto asset issuance in early 2025. However, the excitement buried the seeds of price collapse.
The feast's heat did not last long. BIO adopted an auction mode with an initial circulation ratio higher than most new coins, coupled with the inflated valuation upon listing, making its price appear floating without immediate utility. Early market buying was more driven by narrative and sentiment rather than practical value. When key functions like Launchpad, Staking system, and BioXP points were still in planning, investors quickly realized their tokens could not bring immediate participation rewards or governance rights. The gap between valuation and use cases became the first force causing the price to slide.
BIO's decline was also closely related to timing issues. Core functions were not simultaneously launched on the TGE day, and market confidence began to leak during the waiting period. In ecosystem expansion, Molecule Catalyst's independent operation of Launchpad dispersed funds and attention, weakening the main platform's cohesion. Additionally, as the macro market entered a risk appetite cooling phase, funds quickly withdrew from high FDV projects without immediate cash flow. Lacking continuous news support and product landing rhythm, BIO gradually fell from a star project to a low point of thin trading and price bottoming.
BIO Protocol's Resurgence
Creating a Scientific Research Acceleration Experimental Field
In the first half of 2025, BIO Protocol went through a ups and downs journey - sliding from the narrative peak to price low point, but never slowing its steps. It not only delivered the most brilliant market performance in the DeSci track but also pushed several biological drugs to the clinical trial doorstep, making "on-chain research" smell the breath of real medical verification for the first time.
The price pullback did not deter the team's ambition but instead brought more construction actions: In May, BIO delayed team and advisor token unlocking through community governance, signaling "we are here for the long term". Research progress was equally impressive - VitaRNA and VitaFAST simultaneously started clinical trials in the UAE, taking only 11 months from concept to enrollment, while traditional models often require 4-6 years; 14 compounds predicted by AI with over 85% success rate are awaiting Q3 efficacy readout. Meanwhile, 5 new BioDAOs including QBIO, Long Covid Labs, Curetopia, SpineDAO, and MycoDAO were established, with total fundraising reaching $8.9 million this year, injecting continuous fuel into this high-speed research machine.
V2: Leaping from DeSci 1.0 to DeSci 2.0
Moreover, the BIO team officially launched Bio Protocol V2 in August, aiming to bring research financing and execution into "high-speed mode", solving pain points of DeSci 1.0 stage such as high FDV initial issuance, lack of immediate functions, and ecosystem fragmentation.
[Translation continues in the same professional manner, maintaining the specified translations for specific terms]DeSci aims to subvert the top-down, slow, and closed scientific ecosystem. It uses blockchain's open ledger to make funding flows, research progress, and data usage fully transparent; replaces small-scale review groups with decentralized autonomous organizations (DAOs), allowing research project fates to be decided by a broader community vote; and uses tokenized incentive mechanisms to deeply bind early supporters with research outcomes, thereby attracting more funds and talent. This model can not only shorten the funding cycle of scientific research but also break down disciplinary and geographical barriers through global collaboration, giving innovative ideas that were previously difficult to fund a chance to take root.
In this track, BIO Protocol is undoubtedly a representative and ambitious player. It not only provides early financing channels for biotechnology projects but also builds a comprehensive infrastructure including project screening, fund raising, on-chain liquidity management, data transparency, and research automation. Through BIO, researchers can directly "crowdfund" research funds from the global community, just like launching a crypto project; investors can intervene in the initial stages of projects and share benefits when research achievements are commercialized. Compared to traditional scientific research, BIO aims to create a scientific ecosystem where there is no need to wait for funding approval, not monopolized by a single institution, and where everyone can participate and benefit.
Summary
BIO Protocol has experienced dramatic fluctuations from a high-profile launch early in the year to price bottoming mid-year, and now achieves a staged rebound with the launch of V2. The new low FDV launch, point staking, and liquidity mechanisms have injected new momentum into the ecosystem and reignited market attention to the DeSci track. However, whether it can continue its rebound and bring stable new launch returns still depends on the project's landing rhythm and market environment, with short-term uncertainties still existing.
